Leerink Partners analyst Marc Goodman maintained a Buy rating on Johnson & Johnson (JNJ – Research Report) yesterday and set a price target ...

Johnson & Johnson surpassed earnings expectations with strong sales, but it faces challenges ahead due to patent expirations.

Stifel analyst Rick Wise lowered the firm’s price target on Johnson & Johnson to $155 from $170 and keeps a Hold rating on the shares.

How is one of the world’s largest pharmaceutical companies promoting sustainability and regulatory compliance throughout its ...

The announcement was welcome news for those with major depressive disorder, affecting an estimated 8.3% of the adult ...